Curaleaf (TSX:CURA) Stock May Be Undervalued Despite Its 71% Fall

Curaleaf Holdings stock has seen mixed returns in recent years, and the valuation checks now flag it as looking cheap on several measures even as long term shareholders have experienced sizeable declines. With the share price recently at US$12.99 and sentiment swinging with cannabis reform headlines, the key issue is how to weigh that apparent value against a challenging track record.

• Over the past 5 years the stock has fallen 70.8%, which leaves long term holders deeply underwater and raises the bar for any renewed conviction in Curaleaf Holdings.
• Hopes around cannabis policy changes and margin improvement can support the investment case, while ongoing regulatory uncertainty and pricing pressure remain a significant risk for what the stock is ultimately worth.
• The company screens as undervalued on the broader checks, with a high value score that rates Curaleaf Holdings at 5 and suggests the stock looks inexpensive against several reference points.

For investors, the debate is whether Curaleaf Holdings is now priced low enough to compensate for the volatility and business risks that have driven those long term losses.

Compare Curaleaf Holdings with other beaten down but potentially undervalued ideas by scanning our hand picked 13 high quality undervalued stocks.

Does Curaleaf Holdings Look Undervalued on Sales?

The P/S ratio is often a better fit for Curaleaf Holdings because revenue is more stable to measure than earnings in a sector where profits can be uneven. Curaleaf Holdings currently trades on a P/S of 1.9x, compared with an industry average of about 1.1x for Pharmaceuticals and a peer group average of 3.2x. On raw comparisons the stock does not look especially cheap against the wider industry, although it also does not sit at the higher peer levels.

The valuation model suggests a fair P/S ratio of roughly 2.2x when taking into account Curaleaf Holdings' scale, margins, risks and sector. That is above the current 1.9x, which indicates that the shares screen as undervalued on this measure. Despite the recent share price moves around cannabis reform headlines, the stock still trades at a discount to the fair P/S level implied by these checks.

On the P/S multiple, Curaleaf Holdings stock currently screens as undervalued relative to the fair ratio suggested by its fundamentals and risk profile.

See what the numbers say about this price — find out in our valuation breakdown.

The Curaleaf Holdings Narrative: What Would Justify Today's Price?

Narratives for Curaleaf Holdings pick up after the valuation checks and spell out which combinations of future growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than it is today, using Simply Wall St's Community page as the hub. Each narrative links its number to a clear view of how Curaleaf Holdings' growth, profitability and risk profile might evolve, which you can revisit as fresh data comes through.

One of the top community narratives on Curaleaf Holdings: 27% undervalued

"Industry consolidation and rising distress among subscale operators, especially in the U.S. where price compression is driving exits, position Curaleaf to gain market share and improve operational efficiency..."

Read one of the top narratives on Curaleaf Holdings

Do you think there's more to the story for Curaleaf Holdings? Head over to our Community to see what others are saying!

The Bottom Line

Curaleaf Holdings screens as undervalued on the market multiple checks, which points to a potential disconnect between current sentiment and what the underlying business could justify over time. The challenge is that the stock also carries a difficult long term return profile, so any apparent discount comes with meaningful execution and regulatory risk. For most investors the key question is whether margins and pricing can stabilise enough for the market to reward Curaleaf Holdings with a stronger P/S multiple, rather than treating the current valuation as a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com